Vect-Horus
Business Services · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
27 Bd Jean Moulin, Marseille, Provence-A...Phone Number
+33 491698781Website
www.vect-horus.comRevenue
$6.4 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Vect-Horus
Vect-Horus specializes in enhancing the transport of therapeutic and imaging agents through innovative targeting technology. The company focuses on advancing systemic delivery of RNA-targeted medicines for neurological diseases and has established collaborations with various pharmaceutical partners. Their technology aims to improve the delivery of therapeutics to organs and tumors, particularly in the context of central nervous system therapies. Vect-Horus actively participates in industry events and research collaborations to further their mission.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vect-Horus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Vect-Horus
Product Launch: Get notified when Vect-Horus launches new products
Vect-Horus, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Vect-Horus is spiking on competitors!
Click to see if Vect-Horus had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Vect-Horus has new funding data
Check if Vect-Horus has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Vect-Horus recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Vect-Horus is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Vect-Horus is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Vect-Horus.
Vect-Horus financials insights
Gather financial insights about Vect-Horus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Angel/Seed
$1.8M
2017
Series A
$3M
2018
Series B
$4.2M
2020
Series C
$7.9M
2021
Series D
$14.5M
Vect-Horus Tech Stack
A closer look at the technologies used by Vect-Horus
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Pain Point
Pain Point, Bankruptcy
New Hire
Executive Move
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Funding
Vect-Horus News & Media
Vect-Horus appoints Claudia Fromond as new Director of R&D
Vect-Horus today announced the appointment of Claudia Fromond, PhD, as Director of Research and Development (R&D).Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals
Material Transfer and Evaluation Agreement (MTEA) to initiate a collaboration focused on siRNA delivery for central nervous system (CNS) disorders.RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma
Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to advance innovative Theranostic radiopharmaceuticals to address unmet needs in oncology Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to advance innovative Theranostic radiopharmaceuticals to address unmet needs in oncologySecarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders
Martinsried, Germany, and Marseille, France, July 10, 2025 - Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, and Vect-Horus, an expert in the design and development of molecular vectors to facilitate targeted delivery of therapeutic molecules and imaging agents, today announced that the companies have entered into a strategic research collaboration to develop RNA-targeted therapeutics capable of crossing the
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Vect-Horus
Sign Up For FreeTo access detailed company insights
Vect-Horus specializes in enhancing the transport of therapeutic and imaging agents through innovative targeting technology. The company focuses on advancing systemic delivery of RNA-targeted medicines for neurological diseases and has established collaborations with various pharmaceutical partners. Their technology aims to improve the delivery of... Read More
